| Filed On | Filing |
|---|---|
| 16 Nov 2026 | SCHEDULE 13G/A |
| 16 Nov 2026 | SCHEDULE 13G/A |
| 05 Nov 2026 | 10-Q |
| 05 Nov 2026 |
8-K: Results of Operations and Financial Condition
–Initiated the RECEPTIVE-CD1 Phase 2b clinical trial of SL-325 in Crohn’s disease; 12-week induction data expected in the first half of 2028 – |
| 27 Oct 2026 | SCHEDULE 13G |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 11 Aug 2026 | S-8 |
| 11 Aug 2026 |
8-K: Results of Operations and Financial Condition
–Phase 1 clinical trial results for SL-325 demonstrated a favorable safety profile, a potentially best-in-mechanism immunogenicity profile, and durable DR3 blockade of TL1A binding, potentially enabling prolonged dosing intervals – |
| 11 Aug 2026 | 10-Q |
| 17 Jul 2026 | SCHEDULE 13D/A |
| 07 Jul 2026 |
Form 4: Shukla Abhinav A., Chief Technical Officer
Received 410 shares by exercise or conversion ($1.46K) · Sold 410 shares ($2.87K) · Received 12,153 shares by exercise or conversion ($43.4K) |
| 02 Jul 2026 |
Form 4: Shukla Abhinav A., Chief Technical Officer
Received 23,365 shares by exercise or conversion ($83.4K) · Sold 23,365 shares ($165K) · Received 100 shares by exercise or conversion ($357) · 1 more |
| 02 Jul 2026 |
Form 4: Pandite Arundathy N., Chief Medical Officer
Sold 30,000 shares ($210K) |
| 02 Jul 2026 | 144 |
| 01 Jul 2026 | 144 |
| 30 Jun 2026 | 144 |
| 17 Jun 2026 | SCHEDULE 13G |
| 15 Jun 2026 |
Form 4: Orbimed Advisors Llc, Director and 2 others
Acquired 1,250,000 Pre-Funded Warrants (right to buy) (Open Market Purchase) |
| 15 Jun 2026 | SCHEDULE 13D/A |
| 15 Jun 2026 |
Form 4: Ashiya Mona, Director
Acquired 1,250,000 Pre-Funded Warrants (right to buy) (Open Market Purchase) |
Loading...